Online citations, reference lists, and bibliographies.
← Back to Search

Peritoneal Mesothelioma: PSOGI/EURACAN Clinical Practice Guidelines For Diagnosis, Treatment And Follow-up.

S. Kusamura, V. Képénékian, L. Villeneuve, R. J. Lurvink, K. Govaerts, I. de Hingh, B. Moran, K. van der Speeten, M. Deraco, O. Glehen
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1097/PAS.0000000000000200
Well-differentiated Papillary Mesothelioma With Invasive Foci
A. Churg (2014)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)
10.1111/pin.12053
Well‐differentiated papillary mesothelioma, possibly giving rise to diffuse malignant mesothelioma: A case report
K. Washimi (2013)
10.1179/2049396712Y.0000000016
Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
S. Jane Henley (2013)
10.1097/00000478-198810000-00001
Multicystic Mesothelioma: An Analysis of Pathologic Findings and Biologic Behavior in 37 Cases
S. Weiss (1988)
10.1177/030089161109700105
Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience
G. Lainakis (2011)
10.1002/JSO.10255
Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion
M. Deraco (2003)
10.1007/s12032-018-1125-4
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking
S. Naffouje (2018)
10.1016/j.ejso.2008.09.010
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
H. Yano (2009)
10.1016/j.ejca.2013.11.012
Policy statement on multidisciplinary cancer care.
J. Borràs (2014)
10.1309/AJCPOTO9LBB4UKWC
Well-differentiated papillary mesothelioma of the peritoneum: a diagnostic dilemma on fine-needle aspiration cytology.
Jitendra G. Nasit (2014)
Computed Tomographic Features of Malignant Peritoneal Mesothelioma.
Katsuya Kato (2016)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1081/CNV-120023766
Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma
D. T. Le (2003)
Peritoneal mesothelioma: a review.
A. Bridda (2007)
10.1159/000346187
Benign Cystic Mesothelioma of the Peritoneum: A Rare Case and Review of the Literature
Safi Khuri (2012)
10.1002/jso.21060
The eligibility for local‐regional treatment of peritoneal surface malignancy
V. Verwaal (2008)
10.1016/j.ejso.2018.03.004
Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy.
E. Nizri (2018)
10.1080/02656736.2018.1434902
Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival
S. N. Gilani (2018)
10.1002/1097-0142(19890915)64:6<1336::AID-CNCR2820640628>3.0.CO;2-X
Multilocular peritoneal inclusion cysts (So‐called cystic mesotheliomas)
M. J. Ross (1989)
10.1200/JCO.2007.15.2868
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
G. Simon (2008)
10.1016/j.currproblcancer.2017.03.002
Multicystic peritoneal mesothelioma: A short review.
Chihao Zhang (2017)
10.1016/j.ejso.2017.01.009
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
P. Sugarbaker (2017)
10.1007/978-3-540-30760-0_3
Pathological evaluation and implications of serosal involvement in gastrointestinal cancer.
L. Ludeman (2007)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
Benign cystic mesothelioma in a male patient: surgical treatment by the laparoscopic route.
F. Ricci (1995)
10.1080/02656736.2017.1338363
Diagnostic and therapeutic laparoscopy in assessment and management of patients with appendiceal neoplasms
G. Tan (2018)
10.1016/j.ejso.2009.04.007
Circulating CA125 and diffuse malignant peritoneal mesothelioma.
D. Baratti (2009)
10.1002/jso.21069
Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement
T. Yan (2008)
10.1097/JTO.0000000000000663
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.
W. Travis (2015)
10.1093/jjco/hyt117
Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum.
Y. Lee (2013)
10.1097/PAS.0b013e3182354a79
Well-Differentiated Papillary Mesothelioma of the Female Peritoneum: A Clinicopathologic Study of 26 Cases
A. Malpica (2012)
10.1080/14737140.2017.1340157
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
Eriko Fujimoto (2017)
10.1097/00000478-200110000-00012
Well-Differentiated Papillary Mesothelioma
K. Butnor (2001)
10.1002/dc.21192
Cytomorphologic characteristics of fine needle core biopsy of multicystic peritoneal mesothelioma: A case report and review of the literature
A. Kemp (2010)
10.1002/bjs.8908
Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
L. Iversen (2013)
10.1007/s10552-009-9328-9
Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005
S. Moolgavkar (2009)
10.1245/s10434-015-4962-9
The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
S. Kusamura (2015)
10.5468/ogs.2018.61.1.170
Benign multicystic peritoneal mesothelioma treated with laparoendoscopic single site surgery: a case report and review of the literature
Kyung Sun · Cha (2018)
10.1245/s10434-015-4498-z
Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray
M. Deraco (2015)
10.1016/J.YGYNO.2005.03.031
Well-differentiated papillary mesothelioma of the peritoneum: a pathological analysis and review of the literature.
A. Hoekstra (2005)
10.1245/s10434-013-3358-y
Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis
D. Magge (2013)
10.1053/EJSO.2000.1215
Peritoneal benign cystic mesothelioma: a case report and review of the literature.
S. van Ruth (2002)
10.1093/ANNONC/MDL345
Epidemiology of peritoneal mesothelioma: a review.
P. Boffetta (2007)
10.1007/s00268-018-4634-6
Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience
A. Arjona-Sánchez (2018)
10.1148/rg.282075175
From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation.
A. D. Levy (2008)
10.1007/s00276-008-0456-9
Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas
A. M. Albanese (2008)
10.4103/0019-5278.146897
Global mesothelioma epidemic: Trend and features
C. Bianchi (2014)
10.1002/cncr.20836
Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy
T. Yan (2005)
10.1002/1097-0142(19900115)65:2<292::AID-CNCR2820650218>3.0.CO;2-W
Well‐differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases
D. Daya (1990)
10.1007/s11547-016-0682-x
Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis
A. Laghi (2016)
Malignant transformation in non-recurrent peritoneal cystic mesothelioma Our experience and review of the literature.
G. Santangelo (2016)
10.1245/s10434-007-9475-8
Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
D. Baratti (2007)
Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma.
B. Laterza (2009)
10.1053/HUPA.2003.31
Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status.
R. Sawh (2003)
10.1007/BF01606033
Well-differentiated papillary mesothelioma of the peritoneum: A borderline mesothelioma
K. Bürrig (2005)
10.1245/s10434-017-6033-x
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy
F. Le Roy (2017)
10.1245/s10434-017-6293-5
Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry
K. Votanopoulos (2017)
10.3748/wjg.v19.i39.6689
Diagnosis and treatment of benign multicystic peritoneal mesothelioma.
T. Wang (2013)
10.1111/jgh.13260
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis
Y. Liang (2016)
10.1016/j.jogc.2017.04.038
Remote Recurrence of Benign Multicystic Peritoneal Mesothelioma.
Caroline E. Lee (2017)
10.1111/his.12089
Well‐differentiated papillary mesothelioma: a clinicopathological and immunohistochemical study of 18 cases with additional observation
X. Chen (2013)
10.1097/PGP.0b013e3181f99def
Multicystic mesothelioma caused by endometriosis: 2 case reports and review of the literature.
Y. Kurisu (2011)
10.1016/j.ejca.2016.06.002
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
V. Képénékian (2016)
10.1002/JSO.10081
Malignant transformation of “benign” cystic mesothelioma of the peritoneum
S. González-Moreno (2002)
10.1177/030089160308900107
Peritoneal Cystic Mesothelioma: A Case Series
K. Sethna (2003)
10.1002/1097-0142(197908)44:2<692::AID-CNCR2820440242>3.0.CO;2-6
Multicystic, peritoneal mesothelioma. A report with electron microscopy of a case mimicking intra‐abdominal cystic hygroma (Lymphangioma)
R. Mennemeyer (1979)
10.1016/j.lungcan.2008.08.013
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
G. Cartenì (2009)
10.1016/J.EJSO.2006.05.009
Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
T. Yan (2006)
10.1111/crj.12057
Malignant transformation of well‐differentiated papillary mesothelioma 13 years after the diagnosis: a case report
L. Costanzo (2014)
10.1007/s13193-015-0486-9
Diagnostic Laparoscopy in the Pre-operative Assessment of Patients Undergoing Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancies
R. Seshadri (2016)
10.1097/00000478-199510000-00003
Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
J. Goldblum (1995)
10.1016/S0399-8320(07)73964-7
Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.
D. Elias (2007)
10.1186/s12957-015-0624-4
Effects of sex hormones on survival of peritoneal mesothelioma
Y. Huang (2015)
10.1245/s10434-014-3978-x
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis
J. H. Helm (2014)
10.1245/s10434-014-3977-y
Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome
C. Ihemelandu (2015)
10.1245/s10434-014-4136-1
Port-Site Metastases is an Independent Prognostic Factor in Patients with Peritoneal Carcinomatosis
M. Nunez (2014)
10.1016/j.ejca.2013.05.027
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
D. Baratti (2013)
10.1016/j.ejso.2019.02.030
Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: History, clinical applications, and implementation.
R. N. Low (2019)
10.1016/j.clinimag.2016.10.008
Imaging appearance of benign multicystic peritoneal mesothelioma: a case report and review of the literature.
V. Mehta (2017)
10.1016/j.surg.2013.01.001
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.
H. Alexander (2013)
10.1111/J.1525-1438.2005.00198.X
Benign multicystic peritoneal mesothelioma: cases reports in the family with diverticulosis and literature review
S. Tangjitgamol (2005)
10.1136/thoraxjnl-2016-209825
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial
E. Paci (2017)
10.1097/MNM.0000000000000649
The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma
J. Dubreuil (2017)
10.1245/s10434-008-0234-2
Evaluation of Preoperative Computed Tomography in Estimating Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis
J. Koh (2009)
10.1245/s10434-014-4041-7
Comparison of MRI and CT for Predicting the Peritoneal Cancer Index (PCI) Preoperatively in Patients Being Considered for Cytoreductive Surgical Procedures
R. N. Low (2014)
10.1002/bjs.10723
Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG‐RENAPE)
G. Passot (2018)
10.1155/2012/890450
Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma
L. Bijelić (2012)
10.1016/j.ejso.2018.02.010
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Federica Bruno (2018)
10.1016/j.ejso.2019.03.012
The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma.
R. J. Lurvink (2019)
10.1097/CEJ.0b013e3282f0c0a2
US mesothelioma patterns 1973–2002: indicators of change and insights into background rates
M. J. Teta (2008)
10.1046/j.1365-2559.1997.5460776.x
Pathology of malignant mesothelioma
R. Attanoos (1997)
10.1245/s10434-008-0219-1
Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
D. Baratti (2008)
10.1097/PPO.0b013e3181a58e93
Laparoscopy in the Management of Peritoneal Carcinomatosis
A. Garofalo (2009)
10.1016/J.EJSO.2005.09.016
Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
E. de Bree (2006)
10.3109/15513818509026902
Primitive cystic hepatic neoplasm of infancy with mesothelial differentiation: report of a case.
D. Destephano (1985)
10.1245/s10434-012-2651-5
A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival
Nicholas P. Schaub (2012)
10.1007/s00464-003-9139-0
Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomography
U. Denzer (2003)
10.1016/j.ejso.2017.05.009
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
S. Valmary-Degano (2017)
10.1245/s10434-018-6499-1
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival
V. Verma (2018)
10.1245/s10434-009-0756-2
Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma
D. Baratti (2009)
10.21037/AMJ.2017.08.24
International Early Lung Cancer Action Program: update on lung cancer screening and the management of CT screen-detected findings
M. Chung (2017)
10.1056/NEJMoa1208962
Results of the two incidence screenings in the National Lung Screening Trial.
D. Aberle (2013)
10.1245/s10434-012-2845-x
The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
M. Deraco (2012)
10.1186/1472-6963-10-132
What are the current barriers to effective cancer care coordination? A qualitative study
J. Walsh (2010)
10.1002/cncr.25640
A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database *
T. Yan (2011)
10.1245/s10434-012-2237-2
Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study
D. Baratti (2012)
10.1016/j.humpath.2018.05.001
BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
H. E. Lee (2018)
10.1007/s002619900387
Giant benign cystic peritoneal mesothelioma: US, CT,and MRI findings
A. Özgen (1998)
10.4149/neo_2014_053
Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
H. Kaya (2014)
10.1016/j.ejso.2010.08.130
Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
D. Baratti (2010)
10.3748/WJG.V12.I35.5739
Benign multicystic peritoneal mesothelioma: a case report and review of the literature.
M. Safioleas (2006)
10.1158/1078-0432.CCR-14-0804
Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
R. Hassan (2014)
10.1200/JCO.2003.04.150
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
A. Feldman (2003)
10.1074/jbc.M312372200
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion*
A. Rump (2004)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1007/S00464-001-0052-0
Peritoneal cystic mesothelioma
C. Vara-Thorbeck (2002)
10.1378/CHEST.113.1_SUPPLEMENT.66S
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
10.1093/annonc/mdp307
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
V. Manzini (2010)
10.1016/j.lungcan.2009.10.004
Well-differentiated papillary mesothelioma with invasion to the chest wall.
I. Torii (2010)
10.3816/CLC.2005.N.020
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
P. Jänne (2005)
10.1136/bcr-2013-200212
Diffuse malignant epithelioid mesothelioma in a background of benign multicystic peritoneal mesothelioma: a case report and review of the literature
J. Mino (2014)
10.1002/1097-0142(196311)16:11<1497::AID-CNCR2820161108>3.0.CO;2-W
A combined papillary mesothelioma and adenomatoid tumor of the omentum. Report of a case
J. Hanrahan (1963)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar